$194.00
▼ -1.7% Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 22
▼ 0
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Will FDA Priority Review for Daraxonrasib Redefine Revolution Medicines' (RVMD) Pancreatic Cancer Narrative?
Overview
52-week range
$34
$166
100% of range
Avg surprise (last 3)
-21.8%
Avg reaction (last 2)
+1.6%
100% positive
Latest IV / EM
67%
EM ±11.2% · $190 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-2.29 | $-1.83 | -25.1% | -102.7% | +2.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.61 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-1.31 | $-0.94 | -39.4% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-1.13 | $-1.12 | -0.9% | — | +0.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.94 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.70 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.99 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.92 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | AMC | -$1.93 | -$1.31 | -47.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-445M | — | $-315M | $-265M | $-241M | — | $-176M | $-157M |
| Net income | $-454M | — | $-305M | $-248M | $-213M | — | $-156M | $-133M |
| EPS (diluted) | $-2.29 | — | $-1.61 | $-1.31 | $-1.13 | — | $-0.94 | $-0.81 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $441M | $384M | $217M | $402M | $334M | $543M | $201M | $276M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B | $1.62B |
| Total assets | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B | $1.81B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $754M | $723M | $655M | $564M | $287M | $293M | $197M | $190M |
| Total equity | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B | $1.62B |